A novel vaccine adjuvant comprised of a synthetic innate defence regulator peptide and CpG oligonucleotide links innate and adaptive immunity

Jason Kindrachuk; Håvard Jenssen; Melissa Elliott; Rebecca Townsend; Anastasia Nijnik; Song F. Lee; Volker Gerdts; Lorne A. Babiuk; Scott A. Halperin; Robert E.W. Hancock

doi:10.1016/j.vaccine.2009.05.094

A novel vaccine adjuvant comprised of a synthetic innate defence regulator peptide and CpG oligonucleotide links innate and adaptive immunity

Jason Kindrachuk, Håvard Jenssen, Melissa Elliott, Rebecca Townsend, Anastasia Nijnik, Song F. Lee, Volker Gerdts, Lorne A. Babiuk, Scott A. Halperin, Robert E.W. Hancock

Medicine

Research output: Contribution to journal › Article › peer-review

81 Citations (Scopus)

Abstract

There has been an increased demand for the development of novel vaccine adjuvants that lead to enhanced induction of protection from infectious challenges and development of immunological memory. A novel vaccine adjuvant was developed comprising a complex containing CpG oligonucleotide and the synthetic cationic innate defence regulator peptide HH2 that has enhanced immune modulating activities. The complex of HH2 and the CpG oligonucleotide 10101 was a potent inducer of cytokine/chemokine expression ex vivo, retained activity following extended storage, had low associated cytotoxicity, and upregulated surface marker expression in dendritic cells, a critical activity for a vaccine adjuvant. Immunization of mice with a coformulation of the HH2-CpG complex and pertussis toxoid significantly enhanced the induction of toxoid-specific antibody titres when compared to toxoid alone, inducing high titres of IgG1 and IgG2a, typical of a balanced Th1/Th2 response, and also led to high IgA titres. This study demonstrates the potential application of the HH2-CpG complex as a vaccine adjuvant.

Original language	English
Pages (from-to)	4662-4671
Number of pages	10
Journal	Vaccine
Volume	27
Issue number	34
DOIs	https://doi.org/10.1016/j.vaccine.2009.05.094
Publication status	Published - Jul 23 2009

Bibliographical note

Funding Information:
We gratefully acknowledge financial support from the Bill and Melinda Gates Foundation and Canadian Institutes for Health Research through the Grand Challenges in Global Health Research Initiative. REWH is a recipient of a Canada Research Chair and SAH is a recipient of a CIHR/Wyeth Pharmaceuticals Chair in Clinical Vaccine Research. J.K. was supported by a fellowship from the Canadian Cystic Fibrosis Foundation.

ASJC Scopus Subject Areas

Molecular Medicine
General Immunology and Microbiology
General Veterinary
Public Health, Environmental and Occupational Health
Infectious Diseases

PubMed: MeSH publication types

Journal Article
Research Support, Non-U.S. Gov't

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.vaccine.2009.05.094

Cite this

@article{0c9fc45fd79949eca3a7467b4df95107,

title = "A novel vaccine adjuvant comprised of a synthetic innate defence regulator peptide and CpG oligonucleotide links innate and adaptive immunity",

abstract = "There has been an increased demand for the development of novel vaccine adjuvants that lead to enhanced induction of protection from infectious challenges and development of immunological memory. A novel vaccine adjuvant was developed comprising a complex containing CpG oligonucleotide and the synthetic cationic innate defence regulator peptide HH2 that has enhanced immune modulating activities. The complex of HH2 and the CpG oligonucleotide 10101 was a potent inducer of cytokine/chemokine expression ex vivo, retained activity following extended storage, had low associated cytotoxicity, and upregulated surface marker expression in dendritic cells, a critical activity for a vaccine adjuvant. Immunization of mice with a coformulation of the HH2-CpG complex and pertussis toxoid significantly enhanced the induction of toxoid-specific antibody titres when compared to toxoid alone, inducing high titres of IgG1 and IgG2a, typical of a balanced Th1/Th2 response, and also led to high IgA titres. This study demonstrates the potential application of the HH2-CpG complex as a vaccine adjuvant.",

author = "Jason Kindrachuk and H{\aa}vard Jenssen and Melissa Elliott and Rebecca Townsend and Anastasia Nijnik and Lee, {Song F.} and Volker Gerdts and Babiuk, {Lorne A.} and Halperin, {Scott A.} and Hancock, {Robert E.W.}",

note = "Funding Information: We gratefully acknowledge financial support from the Bill and Melinda Gates Foundation and Canadian Institutes for Health Research through the Grand Challenges in Global Health Research Initiative. REWH is a recipient of a Canada Research Chair and SAH is a recipient of a CIHR/Wyeth Pharmaceuticals Chair in Clinical Vaccine Research. J.K. was supported by a fellowship from the Canadian Cystic Fibrosis Foundation.",

year = "2009",

month = jul,

day = "23",

doi = "10.1016/j.vaccine.2009.05.094",

language = "English",

volume = "27",

pages = "4662--4671",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier BV",

number = "34",

}

TY - JOUR

T1 - A novel vaccine adjuvant comprised of a synthetic innate defence regulator peptide and CpG oligonucleotide links innate and adaptive immunity

AU - Kindrachuk, Jason

AU - Jenssen, Håvard

AU - Elliott, Melissa

AU - Townsend, Rebecca

AU - Nijnik, Anastasia

AU - Lee, Song F.

AU - Gerdts, Volker

AU - Babiuk, Lorne A.

AU - Halperin, Scott A.

AU - Hancock, Robert E.W.

N1 - Funding Information: We gratefully acknowledge financial support from the Bill and Melinda Gates Foundation and Canadian Institutes for Health Research through the Grand Challenges in Global Health Research Initiative. REWH is a recipient of a Canada Research Chair and SAH is a recipient of a CIHR/Wyeth Pharmaceuticals Chair in Clinical Vaccine Research. J.K. was supported by a fellowship from the Canadian Cystic Fibrosis Foundation.

PY - 2009/7/23

Y1 - 2009/7/23

N2 - There has been an increased demand for the development of novel vaccine adjuvants that lead to enhanced induction of protection from infectious challenges and development of immunological memory. A novel vaccine adjuvant was developed comprising a complex containing CpG oligonucleotide and the synthetic cationic innate defence regulator peptide HH2 that has enhanced immune modulating activities. The complex of HH2 and the CpG oligonucleotide 10101 was a potent inducer of cytokine/chemokine expression ex vivo, retained activity following extended storage, had low associated cytotoxicity, and upregulated surface marker expression in dendritic cells, a critical activity for a vaccine adjuvant. Immunization of mice with a coformulation of the HH2-CpG complex and pertussis toxoid significantly enhanced the induction of toxoid-specific antibody titres when compared to toxoid alone, inducing high titres of IgG1 and IgG2a, typical of a balanced Th1/Th2 response, and also led to high IgA titres. This study demonstrates the potential application of the HH2-CpG complex as a vaccine adjuvant.

AB - There has been an increased demand for the development of novel vaccine adjuvants that lead to enhanced induction of protection from infectious challenges and development of immunological memory. A novel vaccine adjuvant was developed comprising a complex containing CpG oligonucleotide and the synthetic cationic innate defence regulator peptide HH2 that has enhanced immune modulating activities. The complex of HH2 and the CpG oligonucleotide 10101 was a potent inducer of cytokine/chemokine expression ex vivo, retained activity following extended storage, had low associated cytotoxicity, and upregulated surface marker expression in dendritic cells, a critical activity for a vaccine adjuvant. Immunization of mice with a coformulation of the HH2-CpG complex and pertussis toxoid significantly enhanced the induction of toxoid-specific antibody titres when compared to toxoid alone, inducing high titres of IgG1 and IgG2a, typical of a balanced Th1/Th2 response, and also led to high IgA titres. This study demonstrates the potential application of the HH2-CpG complex as a vaccine adjuvant.

UR - http://www.scopus.com/inward/record.url?scp=67649494271&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649494271&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2009.05.094

DO - 10.1016/j.vaccine.2009.05.094

M3 - Article

C2 - 19539585

AN - SCOPUS:67649494271

SN - 0264-410X

VL - 27

SP - 4662

EP - 4671

JO - Vaccine

JF - Vaccine

IS - 34

ER -

A novel vaccine adjuvant comprised of a synthetic innate defence regulator peptide and CpG oligonucleotide links innate and adaptive immunity

Abstract

Bibliographical note

ASJC Scopus Subject Areas

PubMed: MeSH publication types

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this